Homepage > Company > Media > Pharma News > 2021 > Alembic Pharmaceuticals Generic Formoterol Fumarate Inhalation Solution Approved

Alembic Pharmaceuticals Generic Formoterol Fumarate Inhalation Solution Approved

Alembic Pharmaceuticals has received FDA approval of its abbreviated new drug application (ANDA) for formoterol fumarate inhalation solution, 20 mcg/2 ml per unit-dose vial, a generic of Mylan Specialty’s Perforomist.

The long-acting beta2-agonist is indicated for twice-daily administration for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

The ANDA, which was developed in partnership with Orbicular Pharmaceutical Technologies, is Alembic’s first inhalational ANDA approval.

November 30, 2021

https://www.fdanews.com/

Read also

AskBio’s AB-1002 gene therapy receives FDA Fast-Track status

The US Food and Drug Administration (FDA) has granted fast-track designation to Bayer subsidiary Asklepios BioPharmaceutical’s (AskBio) investigational gene therapy AB-1002, aimed at...

“Lack of harmonisation in Europe” hindering gene therapy growth

The future of cell and gene therapy access in Europe could be more precarious than across the pond.

Moderna stock on track for the eighth consecutive day of losses

Moderna shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost about 29.6% in the last 12 months and YTD, the st...

Alvotech moves to bring its Humira biosimilar to US market

Hot on the heels of a US Food and Drug Administration (FDA) approval for Alvotech and Teva Pharmaceuticals’ Simlandi (adalimumab-ryvk), Alvotech has announced a long-term agreement w...